Abstract

Reduced expression of caveolin-1 (Cav-1) is an important pathogenic factor in hypertrophic scarring (HTS). Such a reduction can be found in connection with the main known risk factors for HTS, including dark skin, female gender, young age, burn site and severity of the injury. The degree of overexpression of Cav-1 associated with different therapeutic options for HTS correlates with clinical improvements in HTS. This makes endo- or exogenous induction of Cav-1 not only an important therapeutic target for HTS, but also highlights its use as a preventive target to reduce or avoid HTS formation.

Details

Title
Caveolin-1 as a target in prevention and treatment of hypertrophic scarring
Author
Kruglikov, Ilja L 1 ; Scherer, Philipp E 2   VIAFID ORCID Logo 

1  Wellcomet GmbH, Scientific Department, Karlsruhe, Germany 
2  University of Texas Southwestern Medical Center, Touchstone Diabetes Center, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20573995
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41536-019-0071-x
ProQuest document ID
2215529904
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.